Rating Change
Oppenheimer analysts reiterated a Outperform rating on Q32 Bio Inc. (NASDAQ:QTTB) on July 13, 2026.
reiterateNASDAQ:QTTB
Oppenheimer Reiterates Outperform Rating on Q32 Bio Inc. (QTTB)
Rating Change Oppenheimer analysts reiterated a Outperform rating on Q32 Bio Inc. (NASDAQ:QTTB) on July 13, 2026. Market Context Q32 Bio Inc.
Market Context
Q32 Bio Inc. operates in the Healthcare sector. The stock currently trades at $21.38 with a market capitalization of $39.2M.
Analyst coverage from Oppenheimer provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Q32 Bio Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Q32 Bio Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 13, 2026 | Oppenheimer | Outperform | N/A |
| Jul 13, 2026 | Wells Fargo | Overweight | N/A |
| May 22, 2026 | Mizuho | Outperform | N/A |
| May 18, 2026 | Cantor Fitzgerald | Overweight | N/A |
| May 05, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View QTTB Stock Page
Frequently Asked Questions
What does a Outperform rating mean for QTTB?
A Outperform rating from Oppenheimer reflects the analyst's outlook on Q32 Bio Inc. (NASDAQ:QTTB). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the QTTB forecast page.